Journal of Clinical Oncology
Articles in this Issue
Lenvatinib's efficacy in heavily pre-treated metastatic renal cell carcinoma: Insights from a European multicenter study.
510 Background: Lenvatinib-based therapy has shown efficacy in the frontline treatment of metastatic renal cell carcinoma (mRCC). However, there is uncert...
Recurrence and its association with overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients undergoing radical cystectomy (RC): A real-world analysis.
705 Background: MIBC is a heterogenous disease, encompassing T2-T4 tumors with or without nodal disease (T1-T4aN1). A primary treatment modality for MIBC...
Cross resistance among novel androgen receptor axis-targeted agents in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
395 Background: Previous studies reported a cross resistance among novel androgen receptor axis-targeted agents (ARATs) in patients with metastatic castra...
Association between sociodemographic marginalization and receipt of intensified treatment for metastatic castrate-sensitive prostate cancer.
96 Background: Intensified treatment beyond androgen deprivation therapy (ADT) has been shown to improve survival in patients with metastatic castrate-sen...
Trends in inpatient outcomes of bladder cancer: 2008-2021.
674 Background: Bladder cancer is a common malignancy of the urinary tract that is associated with about 16,840 estimated deaths in 2024. With the recent...
Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).
172 Background: Up to 1/3 of pts develop biochemical relapse following primary therapy. Many are not cured with salvage local therapy, likely because of u...
Phase II trial of image-guided oligometastatectomy and radiation therapy in recurrent prostate cancer (SOAR).
38 Background: In a subset of patients with molecular-imaging defined recurrent oligometastatic prostate cancer (PCa), salvage oligometastatectomy with su...
Safety and efficacy of bladder preservation therapy for very high-risk non-muscle-invasive bladder cancer: A single-center, single-arm prospective study (CIP-1).
805 Background: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC) and very high-...
Real-world use and outcomes of darolutamide (DARO), enzalutamide (ENZA), and apalutamide (APA) for nonmetastatic castration-resistant prostate cancer (nmCRPC): Race subgroup analysis.
158 Background: Comparative real-world (RW) data on androgen receptor inhibitor (ARI; DARO, ENZA, APA) use in nmCRPC are limited. DEAR-EXT (NCT06013475) c...
Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials.
813 Background: ADCs have revolutionized the treatment landscape of aUC and are being evaluated as part of combination regimens with checkpoint inhibitors...
Sarcopenia as a marker to assess the surveillance necessity after a 5-year cancer-free period in patients who undergo radical cystectomy: A multi-institutional retrospective study.
871 Background: Although continuous surveillance after a 5-year cancer-free period in patients with bladder cancer (BC) who undergo radical cystectomy (RC...
Expanded access program of cretostimogene grenadenorepvec in patients with non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin.
TPS902 Background: The current American Urological Association (AUA) guideline recommendation for patients diagnosed with High-Risk, BCG-Unresponsive Non-...
Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic markers and tumor gene expression by mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
146 Background: Mevrometostat (PF-06821497; M) is a potent and selective small molecule inhibitor of EZH2. Dose exploration of M in combination with enzal...
Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: First results on outcomes and safety in a German multicenter real-world patient cohort (GUARDIANS).
715 Background: The prospective phase 3 study EV-302 demonstrated superiority regarding efficacy of Enfortumab vedotin plus Pembrolizumab (EVP) compared t...
Phase 1b/2 study of combination <sup>177</sup> Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.
TPS614 Background: Complete response (CR) is a rare event in advanced clear cell renal cell carcinoma (ccRCC). The combination of nivolumab plus cabozanti...
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.
439 Background: N+C showed significant benefits vs S in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for pati...
Evaluating social vulnerability as a key determinant of definitive treatment for Black men with clinically localized prostate cancer.
323 Background: Disparities in prostate cancer (PCa) outcomes have been documented extensively across different racial and ethnic groups and various socia...
Phase Ib/IIa dose escalation and expansion study of [ <sup>212</sup> Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study.
TPS275 Background: Prostate cancer (PC) is the second most common cancer and second leading cause of cancer-related death in men. A recent Lancet Commissi...
Does treatment (Tx) for mental health illness (MHI) impact prostate cancer (PC) Tx and outcomes?
318 Background: We previously showed that men with MHI are 20% less likely to be diagnosed with PC, but when diagnosed, are nearly 2x more likely to have...
Validation of PAM50 for predicting progression in active surveillance: Results from the Miami MAST prospective clinical trial.
238 Background: Active surveillance (AS) has emerged as an increasingly common management strategy for men with low- to favorable intermediate-risk prosta...
Timely BRCA mutation testing in patients with metastatic prostate cancer: A comparative analysis between Medicare Advantage and traditional Medicare.
319 Background: BRCA mutations have emerged as critical biomarkers for guiding the use of PARP inhibitors in metastatic prostate cancer. Timely access to...
A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
815 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) or chemoradiation (CRT)...
Genomic features of prostate cancer patients with and without ductal adenocarcinoma (DA) based on liquid biopsy.
191 Background: Ductal adenocarcinoma (DA) is relatively rare and highly co-existed with prostate adenocarcinoma (AC). This study aims to investigate the...
Concordance between clinical and pathologic staging of T2a–b and T3a renal cell carcinoma.
600 Background: Among patients with renal cell carcinoma (RCC), 5–23% of those with cT1 and smaller cT2 tumors may be upstaged to pT3a disease after surge...
Clinical utility of measuring steady-state plasma level of lenvatinib in advanced renal cell carcinoma.
486 Background: As a multitarget tyrosine kinase inhibitor, lenvatinib (LEN) efficacy and toxicity are dose-dependent, and dose adjustment is common for t...